Principal Financial Group Inc. Sells 9,164 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Principal Financial Group Inc. lessened its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 8.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,678 shares of the company’s stock after selling 9,164 shares during the period. Principal Financial Group Inc. owned about 0.35% of Fulgent Genetics worth $2,272,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Park West Asset Management LLC boosted its stake in shares of Fulgent Genetics by 23.1% during the fourth quarter. Park West Asset Management LLC now owns 424,783 shares of the company’s stock valued at $12,280,000 after purchasing an additional 79,649 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Fulgent Genetics by 11.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,447,153 shares of the company’s stock worth $41,839,000 after purchasing an additional 147,505 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Fulgent Genetics by 14.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 267,313 shares of the company’s stock worth $7,728,000 after purchasing an additional 33,141 shares during the last quarter. Illinois Municipal Retirement Fund increased its holdings in Fulgent Genetics by 5.6% during the 4th quarter. Illinois Municipal Retirement Fund now owns 12,534 shares of the company’s stock valued at $362,000 after purchasing an additional 668 shares during the period. Finally, Teza Capital Management LLC bought a new position in Fulgent Genetics during the 3rd quarter valued at approximately $200,000. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Price Performance

Shares of FLGT stock traded down $0.13 during trading hours on Friday, reaching $19.80. The company’s stock had a trading volume of 24,886 shares, compared to its average volume of 185,283. Fulgent Genetics, Inc. has a one year low of $18.91 and a one year high of $44.09. The firm’s fifty day simple moving average is $20.79 and its 200 day simple moving average is $23.26.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.20. Fulgent Genetics had a negative net margin of 57.72% and a negative return on equity of 2.92%. The business had revenue of $64.49 million for the quarter, compared to the consensus estimate of $65.74 million. On average, equities research analysts anticipate that Fulgent Genetics, Inc. will post -2.12 earnings per share for the current year.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.